StockNews.AI
JAGX
StockNews.AI
7 hrs

Jaguar Health Receives Notice of $250,000 FDA Grant to Fund Confirmatory Trial to Support FDA Approval of Canalevia for Treatment of Chemotherapy-Induced Diarrhea (CID) in Dogs

1. Jaguar Health received a $250,000 FDA grant for Canalevia-CA1. 2. Discussions with partners aim to expand Canalevia's market for general diarrhea.

FDA Approval
-4.65%Current Return
VS
-0.47%S&P 500
$2.1509/25 09:14 AM EDTEvent Start
$2.0509/25 04:06 PM EDTLatest Updated
2m saved
Insight
Article

FAQ

Why Bullish?

The FDA grant bolsters JAGX's financial position and market prospects. Historical examples include similar grants leading to stock price increases for biotech firms.

How important is it?

The grant and potential commercialization significantly impact JAGX's strategy and growth outlook in the animal health market.

Why Long Term?

Success in expanding Canalevia's indications may drive sustained revenue growth over time. Companies like Zogenix saw long-term gains following product indication expansions.

Related Companies

ZGNXHGEN
Company strategy: In discussions with multiple potential animal health company partners to expand the indication and commercialize Canalevia for treatment of general diarrhea globally SAN FRANCISCO, CA / ACCESS Newswire / September 25, 2025 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar"), under its Jaguar Animal Health tradename for the veterinary market, today announced that it has received notice from the U.S. Food and Drug Administration's Center for Veterinary Medicine (CVM) of a $250,000 grant. Canalevia, under the name Canalevia-CA1, is currently conditionally approved for chemotherapy-induced diarrhea (CID) in dogs.

Related News